Ulinastatin

Last updated
Ulinastatin
Clinical data
Trade names Miraclid
AHFS/Drugs.com International Drug Names
Routes of
administration
Intravenous infusion
ATC code
Identifiers
CAS Number
  • 80449-31-6
DrugBank
UNII
KEGG

Ulinastatin, as an urinary trypsin inhibitor (UTI), is a glycoprotein that is isolated from healthy human urine or synthetically produced and has molecular weight of 25 - 40kDa. Highly purified ulinastatin has been clinically used for the treatment of acute pancreatitis, chronic pancreatitis, Stevens–Johnson syndrome, burns, septic shock, and toxic epidermal necrolysis (TEN).

Contents

The drug is used in Japan, where its brand name is Miraclid, as well as in South Korea, China, and India. In India, where it is approved to treat severe sepsis and acute pancreatitis, it is marketed under the brand name Ulihope, Ulicrit-Liquid, Ulinase,U-Tryp in India. It is also known by the names Bikunin and Urinastatin. In China, where it is approved to treat acute pancreatitis, chronic recurrent pancreatitis and acute circulatory failure, it is marketed under the brand name Techpool Roan.

Effectiveness

Ulinastatin is available in countries like China, Japan and India for the management of sepsis and acute pancreatitis.

In Japan, It is clinically used to treat endoscopic retrograde cholangiopancreatography (ERCP)-induced pancreatitis. Studies in Japan have documented a reduction in the incidence of ERCP-induced pancreatitis with the use of ulinastatin. In one study, the incidence of hyperenzymemia and pancreatitis was significantly lower in the ulinastatin group than in the placebo group. [1] In another study, ulinastatin reduced serum, drain amylase, and the incidence of postoperative pancreatitis following pancreaticoduodenectomy. [2]

A study conducted in India found that mortality from all causes over 22 days in subjects with severe pancreatitis was lower among those receiving ulinastatin than those receiving placebo (2.8% versus 18.8%; p=0.048), resulting in a 16% absolute reduction in the risk of death and a relative reduction of 85%. The results indicated that in this population, one life would be saved for every 6.25 subjects treated with ulinastatin. New organ dysfunction was seen in 12 subjects with severe pancreatitis on ulinastatin and 29 on placebo (p=0.0026). [3]

Mechanism of action

Ulinastatin is an acid-resistant protease inhibitor found in human urine and released from the high-molecular-weight precursor I alpha T1. It inactivates many serine proteases, including trypsin, chymotrypsin, kallikrein, plasmin, granulocyte elastase, cathepsin, thrombin, and factors IXa, Xa, XIa, and XlIa. However, although ulinastatin is a protease inhibitor, its activity toward various proteases is relatively weak.

Ulinastatin protein has been found in the brain, liver, kidney, gastrointestinal tract, cartilage, plasma, ovarian follicular fluid, amniotic fluid, and urine. Its mRNA has been detected only in the liver, kidney, heart, lungs, and pancreas. The presence of ulinastatin in certain tissues appears to be due to diffusional uptake and retention through cell surfaces. Ulinastatin also potentiates local anti-proteolytic activity on the extracellular matrix (ECM) during tissue remodeling, possibly through noncovalent binding to TSG-6.

Its secretion is upregulated by pro-inflammatory cytokines, including IL-6, IL-1beta, and TNF-alpha. These cytokines also enhance the synthesis of intracellular I alpha T1 proteins and IL-1beta upregulated ulinastatin. Ulinastatin is implicated in downregulating or suppressing the production of proMMP-1 and proMMP, prostaglandin H2 synthase-2, urokinase, CXC chemokine, pro-inflammatory cytokines, inducible nitric oxide synthase, tissue factor, P-selectin, intercellular adhesion molecule-1, phosphorylation of the extracellular signal-regulated protein kinases, and NF-kappaB activation.

Ulinastatin also suppresses neutrophil accumulation and activity. The genes and proteins regulated by ulinastatin are implicated in the inflammatory process. Therefore, ulinastatin is not just a protease inhibitor, but can also prevent inflammation and cytokine-dependent signaling pathways. In preclinical and clinical studies, ulinastatin protected against acute lung injury, graft ischemia/reperfusion injury, renal failure after cardiopulmonary bypass, severe burn injury, septic shock, preterm birth, tumor invasion, and metastasis. Its anti-metastatic properties may come from the inhibition of cell-bound plasmin activity. Ulinastatin also prevents tumor progression, partially by inhibiting cathepsin B activity. In particular, ulinastatin is thought to inhibit CD44 dimerization and suppress the MAP kinase signaling cascade, thus preventing ECM degradation, tumor cell invasion, and angiogenesis.

Altogether, ulinastatin plays an important role not only in the protection of organ injury during severe inflammation, but also in the inhibition of tumor invasion and metastasis. [4] [5]

Dosage and administration

Patients are typically given one or two 100,000 I.U. vials of ulinastatin (reconstituted in 100 ml of dextrose 5% or 100 ml of 0.9% normal saline) by intravenous infusion over the course of one hour, one to three times per day for three to five days. The dosage may be adjusted according to patients' age and the severity of symptoms. [6]

Related Research Articles

Pancreatitis Inflammation of the pancreas

Pancreatitis is a condition characterized by inflammation of the pancreas. The pancreas is a large organ behind the stomach that produces digestive enzymes and a number of hormones. There are two main types: acute pancreatitis, and chronic pancreatitis. Signs and symptoms of pancreatitis include pain in the upper abdomen, nausea and vomiting. The pain often goes into the back and is usually severe. In acute pancreatitis, a fever may occur, and symptoms typically resolve in a few days. In chronic pancreatitis weight loss, fatty stool, and diarrhea may occur. Complications may include infection, bleeding, diabetes mellitus, or problems with other organs.

Inflammation Physical effects resulting from activation of the immune system

Inflammation is part of the complex biological response of body tissues to harmful stimuli, such as pathogens, damaged cells, or irritants, and is a protective response involving immune cells, blood vessels, and molecular mediators. The function of inflammation is to eliminate the initial cause of cell injury, clear out necrotic cells and tissues damaged from the original insult and the inflammatory process, and initiate tissue repair.

Alpha-1 antitrypsin Mammalian protein found in Homo sapiens

Alpha-1 antitrypsin or α1-antitrypsin is a protein belonging to the serpin superfamily. It is encoded in humans by the SERPINA1 gene. A protease inhibitor, it is also known as alpha1–proteinase inhibitor (A1PI) or alpha1-antiproteinase (A1AP) because it inhibits various proteases. In older biomedical literature it was sometimes called serum trypsin inhibitor, because its capability as a trypsin inhibitor was a salient feature of its early study. As a type of enzyme inhibitor, it protects tissues from enzymes of inflammatory cells, especially neutrophil elastase, and has a reference range in blood of 0.9–2.3 g/L, but the concentration can rise manyfold upon acute inflammation.

Endoscopic retrograde cholangiopancreatography Use of endoscopy and fluoroscopy to treat and diagnose digestive issues.

Endoscopic retrograde cholangiopancreatography (ERCP) is a technique that combines the use of endoscopy and fluoroscopy to diagnose and treat certain problems of the biliary or pancreatic ductal systems. It is primarily performed by highly skilled and specialty trained gastroenterologists. Through the endoscope, the physician can see the inside of the stomach and duodenum, and inject a contrast medium into the ducts in the biliary tree and pancreas so they can be seen on radiographs.

Acute pancreatitis Medical condition

Acute pancreatitis (AP) is a sudden inflammation of the pancreas. Causes in order of frequency include: 1) a gallstone impacted in the common bile duct beyond the point where the pancreatic duct joins it; 2) heavy alcohol use; 3) systemic disease; 4) trauma; 5) and, in minors, mumps. Acute pancreatitis may be a single event; it may be recurrent; or it may progress to chronic pancreatitis.

A trypsin inhibitor (TI) is a protein and a type of serine protease inhibitor (serpin) that reduces the biological activity of trypsin by controlling the activation and catalytic reactions of proteins. Trypsin is an enzyme involved in the breakdown of many different proteins, primarily as part of digestion in humans and other animals such as monogastrics and young ruminants. When trypsin inhibitor is consumed it acts as an irreversible and competitive substrate.

Ascending cholangitis Medical condition

Ascending cholangitis, also known as acute cholangitis or simply cholangitis, is inflammation of the bile duct (cholangitis), usually caused by bacteria ascending from its junction with the duodenum. It tends to occur if the bile duct is already partially obstructed by gallstones.

Cathepsin S

Cathepsin S is a protein that in humans is encoded by the CTSS gene. Transcript variants utilizing alternative polyadenylation signals exist for this gene.

A TNF inhibitor is a pharmaceutical drug that suppresses the physiologic response to tumor necrosis factor (TNF), which is part of the inflammatory response. TNF is involved in autoimmune and immune-mediated disorders such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriasis, hidradenitis suppurativa and refractory asthma, so TNF inhibitors may be used in their treatment. The important side effects of TNF inhibitors include lymphomas, infections, congestive heart failure, demyelinating disease, a lupus-like syndrome, induction of auto-antibodies, injection site reactions, and systemic side effects.

Cathepsin G

Cathepsin G is a protein that in humans is encoded by the CTSG gene. It is one of the three serine proteases of the chymotrypsin family that are stored in the azurophil granules, and also a member of the peptidase S1 protein family. Cathepsin G plays an important role in eliminating intracellular pathogens and breaking down tissues at inflammatory sites, as well as in anti-inflammatory response.

Cathepsin B

Cathepsin B belongs to a family of lysosomal cysteine proteases and plays an important role in intracellular proteolysis. In humans, cathepsin B is encoded by the CTSB gene. Cathepsin B is upregulated in certain cancers, in pre-malignant lesions, and in various other pathological conditions.

SPINK1

Pancreatic secretory trypsin inhibitor (PSTI) also known as serine protease inhibitor Kazal-type 1 (SPINK1) or tumor-associated trypsin inhibitor (TATI) is a protein that in humans is encoded by the SPINK1 gene.

LEKTI

Lympho-epithelial Kazal-type-related inhibitor (LEKTI) also known as serine protease inhibitor Kazal-type 5 (SPINK5) is a protein that in humans is encoded by the SPINK5 gene.

Nafamostat

Nafamostatmesylate (INN), a synthetic serine protease inhibitor, it is a short-acting anticoagulant, and is also used for the treatment of pancreatitis. It also has some potential antiviral and anti-cancer properties. Nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin. The mechanism of action of Nafamostat is as a slow tight-binding substrate, trapping the target protein in the acyl-enzyme intermediate form, resulting in apparent observed inhibition.

An inflammatory cytokine or proinflammatory cytokine is a type of signaling molecule that is secreted from immune cells like helper T cells (Th) and macrophages, and certain other cell types that promote inflammation. They include interleukin-1 (IL-1), IL-12, and IL-18, tumor necrosis factor alpha (TNF-α), interferon gamma (IFNγ), and granulocyte-macrophage colony stimulating factor (GM-CSF) and play an important role in mediating the innate immune response. Inflammatory cytokines are predominantly produced by and involved in the upregulation of inflammatory reactions.

Semapimod

Semapimod (INN), formerly known as CNI-1493, is an investigational new drug which has anti-inflammatory, anti-cytokine, immunomodulatory, antiviral and antimalarial properties.

Pancreatic stellate cells (PaSCs) are classified as myofibroblast-like cells that are located in exocrine regions of the pancreas. PaSCs are mediated by paracrine and autocrine stimuli and share similarities with the hepatic stellate cell. Pancreatic stellate cell activation and expression of matrix molecules constitute the complex process that induces pancreatic fibrosis. Synthesis, deposition, maturation and remodelling of the fibrous connective tissue can be protective, however when persistent it impedes regular pancreatic function.

Angiogenesis is the process of forming new blood vessels from existing blood vessels. It is a highly complex process involving extensive interplay between cells, soluble factors, and the extracellular matrix (ECM). Angiogenesis is critical during normal physiological development, but it also occurs in adults during inflammation, wound healing, ischemia, and in pathological conditions such as rheumatoid arthritis, hemangioma, and tumor growth. Proteolysis has been indicated as one of the first and most sustained activities involved in the formation of new blood vessels. Numerous proteases including matrix metalloproteases (MMPs), a disintegrin and metalloprotease domain (ADAM), a disintegrin and metalloprotease domain with throbospondin motifs (ADAMTS), and cysteine and serine proteases are involved in angiogenesis. This article focuses on the important and diverse roles that these proteases play in the regulation of angiogenesis.

Antipain Chemical compound

Antipain is an oligopeptide that is isolated from actinomycetes and used in biochemical research as a protease inhibitor of trypsin and papain. It was discovered in 1972 and was the first natural peptide found that contained an ureylene group.

Microglia are the primary immune cells of the central nervous system, similar to peripheral macrophages. They respond to pathogens and injury by changing morphology and migrating to the site of infection/injury, where they destroy pathogens and remove damaged cells.

References

  1. Tsujino T, Komatsu Y, Isayama H, Hirano K, Sasahira N, Yamamoto N, Toda N, Ito Y, Nakai Y, Tada M, Matsumura M (April 2005). "Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial". Clinical Gastroenterology and Hepatology. 3 (4): 376–83. doi:10.1016/S1542-3565(04)00671-8. PMID   15822043.
  2. Uemura K, Murakami Y, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T (October 2008). "Randomized clinical trial to assess the efficacy of ulinastatin for postoperative pancreatitis following pancreaticoduodenectomy". Journal of Surgical Oncology. 98 (5): 309–13. doi:10.1002/jso.21098. PMID   18548482. S2CID   39112685.
  3. Journal of the association of physicians of India •August 2013 •VOL. 61 :15-18
  4. Shigetomi H, Onogi A, Kajiwara H, Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Yamada Y, Oi H, Kobayashi H (September 2010). "Anti-inflammatory actions of serine protease inhibitors containing the Kunitz domain". Inflammation Research. 59 (9): 679–87. doi:10.1007/s00011-010-0205-5. PMID   20454830. S2CID   24139496.
  5. Inoue K, Takano H, Yanagisawa R, Yoshikawa T (November 2008). "Protective effects of urinary trypsin inhibitor on systemic inflammatory response induced by lipopolysaccharide". Journal of Clinical Biochemistry and Nutrition. 43 (3): 139–42. doi:10.3164/jcbn.2008059. PMC   2581759 . PMID   19015747.
  6. "Ulinastatin for Injection: Prescribing Information" (PDF). Bharat Serums and Vaccines Ltd.